Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese
× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Worsening MS on nilotinib

  • Max Wolf
  • Max Wolf's Avatar Topic Author
7 years 4 months ago - 7 years 4 months ago #1160 by Max Wolf
Worsening MS on nilotinib was created by Max Wolf
I have a 56yo patient who was diagnosed CML-CP in 2010.
Conventional Ph chr and bcr-abl p210

Commenced Imatinib (IM)
Achieved >4 log reduction in bcr-abl…but then late r lost this response and converted to nilotinib (NIL) by early 2014

The interesting part is that the patient has multiple sclerosis (MS).

From neurologist – he has high clinical suspicion that her MS has been exacerbated, both in terms of frequency and severity since starting NIL

There is no doubt conceptually, MOA via TK-dep pathways - particularly PDGFR, c-kit, SRC – this is certainly feasible
Interesting there are mouse models looking at IM in MS and other autoimmune diseases

It has also been a particular cold winter in Melbourne!

It terms response to NIL.
Commenced late 2013/early 2014 – has achieved >4-log reduction (pretty quickly) and sustained since

So our questions

1. What is the likelihood of this association with nilotinib and exacerbation of MS?

2. Safety of considering trial cessation NIL

3. Alternative TKI…lesser of evils given her comorbidity 9Das and PON are also potent inhibitor PDGFR, c-Kit, SRC)
Last edit: 7 years 4 months ago by Melissa Davis-Bishop.
Quick Reply

Reply to Max Wolf

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
  • Tim Hughes
  • Tim Hughes's Avatar Topic Author
7 years 4 months ago #1161 by Tim Hughes
Replied by Tim Hughes on topic Worsening MS on nilotinib
The case is certainly a challenging one.
In response to your questions:

1. I would be quite suspicious that nilotinib is exacerbating her MS. Certainly enough suspicion to suggest that you shouldn’t use nilotinib any more.

2. I think it would be perfectly reasonable to attempt TFR now since you are forced to stop nilotinib and want to avoid a TKI if at all possible in case it is a class effect. Her chances of successful TFR are not high because she developed resistance to imatinib and has only had MR4 for about 2 years on nilotinib. So chances may only be 20% but you don’t lose a lot by trying. At least she gets a break for a few months which may be informative regarding symptoms.

3. With IM and NIL out of the picture I agree it is between dasatinib and ponatinib if you have to restart. You would hate to add vascular problems to her current neurological deficit so I would choose dasatinib. Have you searched for MS in the dasatinib setting? I haven’t heard of it. The alternative would be ABL001 which would be fine as long as the MS progression isn’t due to ABL inhibition which seems unlikely. Is that a practical option? Is the Phase III third line study of ABL001 versus bosutinib coming to Melbourne?
Quick Reply

Reply to Tim Hughes

Your e-mail address will only be available to administators.
Go to editor..
Note: BBcode and smileys are still usable.
Moderators: Nicola, arlene